Personalized Medicine – 2018
The largest online store of market research reviews ResearchAndMarkets.com Since February 5, it offers to purchase a Personalized Medicine – Scientific and Commercial Aspects report written by employees of Jain PharmaBiotech (Personalized Medicine – Scientific and Commercial aspects).
The review describes the most modern concepts of developments in the field of personalized medicine based on the methods of pharmacogenomics, pharmacogenetics, pharmacoproteomics and metabolomics. An important role in this area belongs to the basic technologies of molecular diagnostics, especially the methods of genotyping single nucleotide polymorphisms, or snips (from the English single nucleotide polymorphism, SNP). Biomarkers also play an important role in personalized medicine. The diagnostic process is integrated with therapy in order to select a treatment method, as well as monitoring the results.
In modern medicine, special attention is paid to the early detection and prevention of the development of diseases. Biochips/microplates and next-generation sequencing technologies are also important. The concept of personalized medicine described in this report remains the best way to integrate new technologies, such as nanobiotechnology, to improve healthcare. And finally, bioinformatics is a necessary tool for analyzing huge amounts of data obtained using various technologies.
Pharmacogenetics – the field of studying the influence of genetic factors on the effects of drugs and metabolism – is used to predict undesirable adverse reactions of the body to drugs. Several enzymes are involved in the metabolism of drugs, the most important of which belong to the cytochrome P450 family. Information about the effect of polymorphisms of genes encoding these enzymes is used in the research and development of new drugs, as well as in their clinical application.
Currently, cost-effective methods of genotyping are being developed, the results of which would be nice to include in the medical history to facilitate the selection of individual therapy. Pharmacogenomics, which overlaps with pharmacogenetics, but represents a separate direction, works with the use of genomics data for the research and development of new drugs. She studies how the mechanisms of drug action on cells are determined by the profiles of gene expression. Facrmacoproteomics makes an important contribution to personalized medicine, as it provides the most functional reflection of the inter-patient variability detected during genotyping. The report also describes a "pharmacometabolomic" approach to personalizing drug therapy.
Biological treatments, such as those using the patient's own cells, are generally considered personalized. For example, anti-cancer vaccines are made from the patient's own tumor cells. Individualized therapeutic strategies involving the use of monoclonal antibodies can be used against specific genetic and immunological targets. Ex vivo gene therapy involves the genetic modification of the patient's cells in vitro before their reimplantation into the body.
The review describes personalized treatment methods for specific therapeutic areas, for the development of which various technologies are integrated. Examples include the use of genotyping in the fight against drug resistance to HIV infection, as well as the personalization of cancer therapy, the use of neuroleptics in schizophrenia, antidepressant therapy, antihypertensive therapy and the treatment of neurological disorders. Despite the fact that genotyping is not yet a routine clinical practice, it is expected that it will acquire this status by 2020.
Several players are involved in the development of personalized therapy methods. Pharmaceutical and biotech companies have assumed a leading role in this area, as in the future they plan to become entrepreneurs in the field of healthcare, and not just technology developers and manufacturers of medicines.
In the process of developing personalized medicines, ethical issues inevitably arise, mainly related to the field of genetic testing. They are discussed in parallel with social issues and the need to consider racial characteristics when developing personalized treatment methods. Regulatory issues are considered primarily on the basis of the pharmacogenomics guidelines of the U.S. Food and Drug Administration (FDA).
Improving the effectiveness and safety of treatment by individualizing it has its advantages in terms of financial conditions. The report provides information demonstrating that personalized medicine will be cost-effective in the conditions of the existing healthcare system. For pharmaceutical companies, market segmentation may not leave room for traditional blockbuster drugs, but small exclusive markets for personalized medicines will also bring profit. The market opportunities of such a system are described taking into account market forecasts for the period 2016-2026.
The second part of the report contains descriptions of 326 companies involved in the development of technologies for personalized therapy, as well as 589 institutions cooperating with them. Finally, the bibliography presented in the report contains more than 750 selected publications. The report also contains 85 tables and 42 images.
Key topics covered:
Part I: Scientific and commercial aspects
Resume
1. Basic aspects
2. Molecular diagnostics in personalized medicine
3. Pharmacogenetics
4. Pharmacogenomics
5. The role of pharmacoproteomics
6. The role of metabolomics in personalized medicine
7. Personalized biological treatments
8. Personalized non-pharmacological treatment methods
9. Personalized medicine in the main therapeutic areas
10. Personalized Cancer medicine
11. Prospects for the development of personalized medicine
12. Ethical, legal and regulatory aspects of personalized medicine
13. Commercial aspects of personalized medicine
14. Used literature
Part II: Companies
1. Companies involved in the development of personalized medicine
You can get acquainted with the detailed description of the review and order it at a price from 6 000 to 18 000 US dollars, depending on the format, on the website ResearchAndMarkets.com .
Evgenia Ryabtseva, portal "Eternal Youth" http://vechnayamolodost.ru Based on the materials of GlobeNewswire: Global Personalized Medicine Market Report 2018: Profiles of 326 Companies with 589 Collaborations.